These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 7907347)

  • 1. Pharmacokinetics of orally administered levocabastine in patients with renal insufficiency.
    Zazgornik J; Huang ML; Van Peer A; Woestenborghs R; Heykants J; Stephen A
    J Clin Pharmacol; 1993 Dec; 33(12):1214-8. PubMed ID: 7907347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of ritanserin in patients undergoing hemodialysis.
    Zazgornik J; Kuska J; Kokot F; Koch S; Van Peer A; Huang ML; Heykants J
    J Clin Pharmacol; 1991 Jul; 31(7):657-61. PubMed ID: 1910052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of effect of erythromycin and ketoconazole on the pharmacokinetics and pharmacodynamics of steady-state intranasal levocabastine.
    Pesco-Koplowitz L; Hassell A; Lee P; Zhou H; Hall N; Wiesinger B; Mechlinski W; Grover M; Hunt T; Smith R; Travers S
    J Clin Pharmacol; 1999 Jan; 39(1):76-85. PubMed ID: 9987703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and safety of ebastine in healthy subjects and patients with renal impairment.
    Noveck RJ; Preston RA; Swan SK
    Clin Pharmacokinet; 2007; 46(6):525-34. PubMed ID: 17518511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacology of new histamine H1 receptor antagonists.
    Simons FE; Simons KJ
    Clin Pharmacokinet; 1999 May; 36(5):329-52. PubMed ID: 10384858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pharmacokinetic properties of topical levocabastine. A review.
    Heykants J; Van Peer A; Van de Velde V; Snoeck E; Meuldermans W; Woestenborghs R
    Clin Pharmacokinet; 1995 Oct; 29(4):221-30. PubMed ID: 8549024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.
    De Martin S; Orlando R; Bertoli M; Pegoraro P; Palatini P
    Clin Pharmacol Ther; 2006 Dec; 80(6):597-606. PubMed ID: 17178261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of loratadine in patients with renal insufficiency.
    Matzke GR; Halstenson CE; Opsahl JA; Hilbert J; Perentesis G; Radwanski E; Zampaglione N
    J Clin Pharmacol; 1990 Apr; 30(4):364-71. PubMed ID: 2140371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of emedastine difumarate, a new anti-histaminic agent in patients with renal impairment.
    Joukhadar C; Herranz U; Pernerstorfer T; Assandri A; Klein N; Schrolnberger C; Lackner E; Eichler HG; Müller M
    Eur J Clin Pharmacol; 2001 Mar; 56(12):905-10. PubMed ID: 11317479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of cefadroxil in normal subjects and in patients with renal insufficiency.
    Humbert G; Leroy A; Fillastre JP; Godin M
    Chemotherapy; 1979; 25(4):189-95. PubMed ID: 456077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of severe renal failure and haemodialysis on the pharmacokinetics of levosimendan and its metabolites.
    Puttonen J; Kantele S; Kivikko M; Häkkinen S; Harjola VP; Koskinen P; Pentikäinen PJ
    Clin Pharmacokinet; 2007; 46(3):235-46. PubMed ID: 17328582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and safety of ebastine in patients with impaired hepatic function compared with healthy volunteers: a phase I open-label study.
    Lasseter KC; Dilzer SC; Vargas R; Waldman S; Noveck RJ
    Clin Pharmacokinet; 2004; 43(2):121-9. PubMed ID: 14748620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of ceftazidime in patients with renal insufficiency and in those undergoing hemodialysis.
    Ohkawa M; Nakashima T; Shoda R; Ikeda A; Orito M; Sawaki M; Sugata T; Shimamura M; Hirano S; Okumura K
    Chemotherapy; 1985; 31(6):410-6. PubMed ID: 3908006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical pharmacokinetics of mizolastine.
    Lebrun-Vignes B; Diquet B; Chosidow O
    Clin Pharmacokinet; 2001; 40(7):501-7. PubMed ID: 11510627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of cefepime in subjects with renal insufficiency.
    Barbhaiya RH; Knupp CA; Forgue ST; Matzke GR; Guay DR; Pittman KA
    Clin Pharmacol Ther; 1990 Sep; 48(3):268-76. PubMed ID: 2401125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolism of flecainide.
    Conard GJ; Ober RE
    Am J Cardiol; 1984 Feb; 53(5):41B-51B. PubMed ID: 6364769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic study of an oral cephalosporin, cefdinir, in hemodialysis patients.
    Hishida A; Ohishi K; Nagashima S; Kanamaru M; Obara M; Kitada A
    Antimicrob Agents Chemother; 1998 Jul; 42(7):1718-21. PubMed ID: 9661010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of the hemodialysis on the half-life of practolol in patients with severe renal failure.
    Harvengt C; Desager JP; Muschart JM; Tjandramaga YB; Verbeeck R; Verberckmoes R
    J Clin Pharmacol; 1975; 15(8-9):605-10. PubMed ID: 1167308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic optimisation of histamine H1-receptor antagonist therapy.
    Simons FE; Simons KJ
    Clin Pharmacokinet; 1991 Nov; 21(5):372-93. PubMed ID: 1685361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of oral talinolol following a single dose and during steady state in patients with chronic renal failure and healthy volunteers.
    Krueger M; Achenbach H; Terhaag B; Haase H; Richter K; Oertel R; Preiss R
    Int J Clin Pharmacol Ther; 2001 Feb; 39(2):61-6. PubMed ID: 11270803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.